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656 CORRESPONDENCE
of less than 6- 5 mg per kg) is currently the drug of first choice.“ 
If these measures fail, a wide variety of other medications have 
been advocated. These include thalidomide,3 dapsone, oral
gold,5 alpha interferon,6 and retinoids/ All have been shown, 
in at least one study, to produce a good clinical response in 
patients with DLE who have failed to respond to the 
combination of topical steroids, sunblocks and hydroxychlor­
oquine. However, in our experience, we have encountered a 
number of patients with active DLE who have failed to respond 
to the above treatments. In addition, the toxicity of some 
treatments, such as thalidomide, oral gold or retinoids, may 
limit their use. We were therefore interested to assess the 
potential use of MTX in the management of DLE, which has 
not been reported previously, and which might be a useful 
addition to the therapeutic armamentarium for this condition. 
Low-dose weekly oral MTX is a relatively safe drug and 
hepatotoxicity is usually limited to psoriatics whose condition 
is complicated by a secondary factor such as alcohol excess, 
diabetes mellitus, arsenic ingestion, or obesity. The American 
Rheumatism Association does not recommend routine pre­
treatment liver biopsy for patients with uncomplicated 
rheumatoid arthritis receiving MTX,8 as very few problems 
have been reported with its use in this condition. Side-effects 
reported in patients with SLE have included neutropenia and
oral ulceration, and have tended to be confined to those
1
patients with active disease with renal impairment. Thus, 
short-term treatment of DLE with MTX is most unlikely to be 
complicated by any significant side-effects, in the absence of 
an additional factor. Possible mechanisms of action of MTX in 
DLE might include inhibition of T-cell activation and the 
inhibition of migration of inflammatory cells into the affected 
area.
As only a small number of patients were included in this 
study, the conclusions drawn must be limited. However, the 
reasonable response seen in two of the four patients suggests 
that MTX may be of help in patients with therapy-resistant 
DLE which has failed to respond to hydroxychloroquine, and 
in whom other treatments, such as thalidomide, oral gold or 
retinoids, have either failed or are contraindicated.
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T ran sg lu tam in ase-p ositive  cells  in  psoriatic  ep iderm is during  
trea tm en t w ith  calcitriol ( l o t ,2 5  d ih yd roxy  v itam in  D j)  an d  
tacalcitol ( l a , 2 4  d ih yd roxy  v ita m in  D ?)
Sir, T he keratinization process in human epidermis involves 
the formation of an insoluble cross-linked protein envelope. 
Involucrln, filaggrin and other major precursor proteins of the 
corniiied cell envelope are expressed late during epidermal 
differentiation.1 Involucrin expression starts in the upper 
spinous cell layers in normal human skin. Filaggrin 
expression is restricted to the granular layer and the stratum 
corneum.3 These and other precursor proteins become cross- 
linked by the activity of transglutaminase K, the rate limiting 
enzyme in the formation of the corniiied envelope, via e-(7 ~ 
glutamyl) lysine isopeptide bonds.4
It has been demonstrated that membrane-associated 
transglutaminase activity and the number of cross-linked 
envelopes are markedly increased in psoriatic skin. It is also 
well established that in psoriatic epidermis involucrin expres­
sion is significantly increased, whereas filaggrin expression is 
decreased or even absent.
In keratinocytes in vitro, it has been demonstrated that 
corniiied envelope formation and transglutaminase activity 
are enhanced by calcitriol (la-,25 dihydroxy vitamin I)(). 
tacalcitol (Irv,24 dihydroxy vitamin Dj), and calcipotriol.'l)
we repoi that In ,2 5 jD i and In ,24
*
(OI'DiDj reduce the expression of involucrin and increase 
filaggrin expression in psoriatic skin.(>’10
A mouse monoclonal antibody (Igt52a) against human 
keratinocyte transglutaminase (BTT) has become available for
t I I ! j |*i ,ec e.
the present investigation was to examine the effect of l« ,2 5
2 D) and of l a , 24 (Oil)_> l)5 on the expression of human 
keratinocyte transglutaminase in vivo during treatment of 
psoriatic plaques with these, derivatives.
Twenty patients with stable psoriasis vulgaris were included 
in this study. Ten patients were treated with calcitriol in 
petrolatum (3 /¿g/g) twice daily. Before treatment, and after I , 
2 and 4 weeks of treatment, punch biopsies ( J rnm) were 
taken from the psoriatic lesions. Calcitriol was obtained from 
Solvay Duphar, Amsterdam, the Netherlands. The other 10 
patients were Ire; 
daily on one half of the body, and the ointment base alone 
on the other half, for 8 weeks. Before treatment, and after 8 
weeks of treatment, punch biopsies (3 mm) were taken from 
both body halves.
To visualize transglutaminase type 1, which is expressed
once
during differentiation of the epidermis, we used immuno-
(<"> 1995 British Association of Dermutologists, British Journal o f Denmtologu, 1 33, 65 5 -66
0>/c0 80
70
60
50
40
30
20
10
0
Wk 0 Wk 4 Wk 0 Wk 4
Tip Interpapillary
Figure 1. Plasma membrane-bound transglutaminase before treat­
ment, and after 4 weeks of treatm ent with calcitrici 3 
petrolatum, twice daily (n =  10). Mean ±  standard error of the mean,
peroxidase staining 
glut a m i n a se ( m o u se
an anti-human keratinocyte trans­
i s  m
was
glutaminase expression was assessed by calculating the ratio 
positive cell layers/total cell layers of the living epidermis. This 
procedure was performed at two sites: at: the tip of a dermal 
papilla, and in the interpapillary region. On every slide, two 
representative areas were examined, and the mean of these 
observations was assessed. The Wilcoxon ranking test for 
matched pairs was used for statistical analysis.
The calcitriol-treated lesions showed a statistically signifi­
cant reduction of transglutaminase expression at the tip of a 
dermal papilla after 4 weeks of treatment (P < 0*03).
ary region, the transgluti 
tendency to decrease after 4 weeks 
(P < 0-075).
The tacalcitol-treated lesions also showed a statistically 
significant decrease of transglutaminase expression at the tip 
of a dermal papilla (P < 0*03), whereas the expression in the
interpapillary zone was not significantly a fleeted by 
treatment (P <  0*125). The transglutaminase expression in 
the biopsies of the lesions treated with placebo did not change
(I 0*2 in both areas). Figures 1 and 2
demonstrate the mean values ±  the standard error of the 
mean. Figure 3 shows the distribution of transglutaminase 
before and after 4 weeks of treatment with calcitriol.
It has been demonstrated that membrane-associated 
transglutaminase activity and the number of cross-linked
envelopes are markedly increased in psoriatic skin 
and tenfold, respectively.5 Recently, we demonstrated by 
immunohistoehemistry that the number of transglutaminase- 
positive cells is markedly increased in lesional skin compared 
with the clinically uninvolved skin of psoriatic patients. The 
distribution pattern of transglutaminase comprised relatively 
more cell layers compared with the distribution pattern of 
involucrin. To date, the trigger for 
transglutaminase in psoriatic skin has still to be Identified. It is
at involucrin expression stimulates the 
expression of its cross-linking enzyme directly. Alternatively,
Figure 2. Plasma membrane-bound 
transglutaminase before treatment, and after 
8 weeks of treatment with tacaleitol ointment 
(4/tg/g) once daily and placebo ointment 
once daily (n =  10). Mean ±  standard error 
of the mean, (a) Suprapapillary distribution 
pattern, (b) Interpapillary distribution.
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Treatment of recurrent aphthous stomatitis with 
pentoxifylline
Sir, Recurrent aphthous stomatitis (RAS) is one of the most 
common diseases affecting the oral mucosa. Many drugs, 
including analgesics, antibiotics, topical and systemic corti 
costeroids, dapsone, colchicine and thalidomide, have been 
used to relieve pain and to reduce the frequency of relapse.
They are not always effective, and side-effects are a
I
complicating factor. Pentoxifylline (PTX) is a methylxanthine 
derivative with haemorrheologlcal and antithrombotic prop­
erties.2 Recent experimental arid clinical observations have 
demonstrated that PTX also has immunomodulating and anti­
inflammatory activities,3 which seem to be related, at least in 
part, to the inhibitory effect of PTX on tumour necrosis factor 
(TNF)-alpha production.4 Thalidomide, which is one of the 
treatments of choice for severe RAS,15 also inhibits TNF-alpha 
production/1 This observation led us to speculate that PTX and 
thalidomide could share certain therapeutic effects, such as 
the prevention of RAS.7 , we six pi
with RAS who were successfully treated with PTX. Oral 
therapy with PTX (400 mg two-three times daily) suppressed 
the recurrence of aphthae in five patients, and led to a 
reduction in the number and duration of ulcers, with 
symptomatic improvement, in one patient.8 We now report 
22 additional cases.
Twenty-two patients (14 women and eight men) between 
19 and 75 years of age (mean 34 years), were enrolled in this 
open study. All the patients were diagnosed as having minor 
RAS, and had a disease duration of 2 -8  years (mean 3*5 
years). They all had multiple oral aphthous ulcers 
lasted for 7 -15  days, and experienced recurrences at 
every 2 months. Seventeen patients had neither clinical nor 
analytical evidence of any underlying systemic or cutaneous 
disease. The remaining five patients suffered from
itis (which was treated with low-dose oral corticosteroids 
and mesalazine), rheumatoid arthritis (treated 
steroidal anti-inflammatory drugs), subacute cutaneous lupus 
erythematosus (treated with topical corticosteroids and sun- 
screening cream), anorexia nervosa and Parkinson's disease. 
All the patients received oral therapy with PTX at a dose of 
400 mg three times daily. Patients were studied monthly for a 
6-month oerlod. Two
non-
the drug was
month. The drug was well tolerated by the remaining 20
pa c\ s. No
the course of treatment
were observed in 11 patients (50%), including those cases
with anorexia nervosa, ulcerative md
cutaneous lupus erythematosus. Six patients (27%) showed 
recurrence of the lesions during the period of the study, but 
there was a reduction in the number and duration of ulcers, as 
well as in the pain and difficulty with eating. Recurrence of 
aphthous ulcers without symptomatic improvement was
The present study, and our 
that continuous PTX treatment can or
reduce its severity, In most patients. In addition,
©  1995 British Association of Dermatologists, British Journal of Dermatology, 133, 6 5 3 -6 6 7
